Jefferies has lowered its price target for Novo Nordisk from DKK275 to DKK270 and maintained a 'hold' rating due to uncertainties around GLP-1 drug pricing and the launch of the oral Wegovy weight-loss pill. The broker warns that oral Wegovy may cannibalize sales of injectable products, leading to stagnant overall growth in Novo's GLP-1 franchise. Competition from Eli Lilly's upcoming oral obesity drug orfoglipron adds further risk. Jefferies also notes potential downside if the oral Wegovy launch underperforms or rival drugs show strong data, with a possible share price drop to DKK200.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
